Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Clinical Genomics Interpretation Platforms Global Market Report 2026 | Capitalize on AI and Cloud Growth Through 2030 with Thermo Fisher, Illumina, QIAGEN, and Tempus AI

globenewswire.com
TMO Thermo Fisher Scientific is mentioned as a key player in the global clinical genomics interpretation platforms market, which is experiencing rapid growth driven by AI and cloud adoption. The article does not provide specific sentiment towards Thermo Fisher itself but includes it in a list of major companies. ILMN Illumina is mentioned as a key player in the global clinical genomics interpretation platforms market, which is experiencing rapid growth driven by AI and cloud adoption. The article does not provide specific sentiment towards Illumina itself but includes it in a list of major companies. QGEN QIAGEN is mentioned as a key player in the global clinical genomics interpretation platforms market, which is experiencing rapid growth driven by AI and cloud adoption. The article does not provide specific sentiment towards QIAGEN itself but includes it in a list of major companies. VERA Veracyte is highlighted positively due to its acquisition of C2i Genomics, which added AI-driven minimal residual disease technology to its cancer diagnostics platform, strengthening its capabilities in treatment monitoring.

Clinical Genomics Interpretation Platforms Global Market Report 2026 | Capitalize on AI and Cloud Growth Through 2030 with Thermo Fisher, Illumina, QIAGEN, and Tempus AI Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Clinical Genomics Interpretation Platforms Market Global Report 2026" has been added to ResearchAndMarkets.com's offering.

The global clinical genomics interpretation platforms market is experiencing rapid growth, supported by increased use of next-generation sequencing, expanding genomic research initiatives and rising demand for personalized healthcare. The market is projected to grow from $1.52 billion in 2025 to $1.74 billion in 2026, representing a compound annual growth rate (CAGR) of 14.5%.

Historical market growth has been driven by greater adoption of next-generation sequencing technologies, increased funding for genomic research and the development of clinical bioinformatics capabilities within hospitals and diagnostic laboratories. The rising prevalence of cancer and genetic disorders has also increased demand for platforms that can analyze genomic information and support accurate clinical interpretation.

The clinical genomics interpretation platforms market is forecast to reach $2.93 billion by 2030, expanding at a CAGR of 14%. Key growth factors include the adoption of artificial intelligence-powered genomic interpretation, growing demand for precision medicine and targeted therapies, and increased integration of cloud-based healthcare analytics. Population-scale genomic screening programs and efforts to establish standardized, interoperable clinical genomic databases are also expected to create significant market opportunities.

Artificial intelligence is emerging as a major clinical genomics market trend, enabling faster variant interpretation and more automated clinical decision support. Healthcare providers and laboratories are increasingly adopting cloud-based genomic data platforms to manage large-scale sequencing analysis. At the same time, multi-omics integration is strengthening precision medicine workflows by combining genomic data with other molecular and clinical information.

Interoperable genomic databases are supporting research collaboration across healthcare institutions, while real-time genomic reporting tools are helping clinicians accelerate diagnosis and treatment planning. These capabilities are becoming increasingly important as health systems seek to improve the speed, consistency and clinical value of genomic testing.

The expanding adoption of precision medicine is a primary driver of clinical genomics interpretation platform demand. Advances in genomics and molecular diagnostics allow healthcare professionals to select therapies based on patients' genetic and molecular characteristics, potentially improving treatment effectiveness while reducing adverse effects. Clinical genomics platforms support these initiatives by integrating sequencing results, variant interpretation and patient-specific clinical information to inform diagnoses and treatment strategies.

Momentum in personalized therapies further highlights the importance of genomic interpretation. According to the Personalized Medicine Coalition, the U.S. Food and Drug Administration approved 16 new personalized therapies for patients with rare diseases in 2023, compared with six approvals in 2022. This increase demonstrates the growing role of genomic insights in therapeutic development and clinical care.

Technology providers are responding by developing integrated clinical next-generation sequencing platforms that improve workflow standardization, genomic analysis and clinical decision-making. In March 2026, BGI Genomics launched SIROmics, an integrated solution supporting high-throughput clinical genetic testing and genomic interpretation. The solution combines laboratory automation, bioinformatics analysis, reporting and quality control to establish an end-to-end workflow for clinical sequencing operations.

SIROmics integrates sample preparation, sequencing setup, data analysis, validation and quality control within a standardized in-hospital testing environment. It also includes GenSIRO, an automated wet-laboratory solution compatible with multiple sequencing instruments. The technology is designed to improve operational efficiency and reduce manual coordination within clinical laboratories.

Strategic acquisitions are also shaping the competitive environment. In February 2024, Veracyte acquired C2i Genomics for $70 million. The transaction added artificial intelligence-driven, whole-genome minimal residual disease technology to Veracyte's cancer diagnostics platform. The integration is intended to strengthen treatment monitoring and disease recurrence testing capabilities across the cancer care continuum.

North America was the largest clinical genomics interpretation platforms market in 2025, reflecting its established genomic research infrastructure, advanced healthcare systems and strong adoption of precision medicine. Asia-Pacific is expected to be the fastest-growing region during the forecast period. The market spans Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy and Spain.

Markets Covered:

1) By Component: Software; Services

2) By Organization Size: Large Healthcare Enterprises; Mid-Sized Healthcare Organizations; Small And Specialty Clinics

3) By Deployment Mode: Cloud-Based; On-Premises

4) By Application: Oncology; Rare Diseases; Infectious Diseases; Pharmacogenomics; Reproductive Health; Neurological Disorders; Other Applications

5) By End User: Hospitals And Clinics; Research And Academic Institutes; Diagnostic Laboratories; Other End Users

Subsegments:

1) By Software: Genomic Data Analysis Software; Variant Interpretation And Annotation Software; Clinical Decision Support Software; Genomic Visualization And Reporting Software; Artificial Intelligence Based Genomic Interpretation Platforms

2) By Services: Implementation And Integration Services; Genomic Data Interpretation Services; Consulting And Advisory Services; Training And Technical Support Services; Maintenance And Upgrade Services

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Key Attributes:

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/azs2x9

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.